AlloVir, Inc. (NASDAQ:ALVR) Short Interest Up 5.7% in March

AlloVir, Inc. (NASDAQ:ALVRGet Free Report) saw a large growth in short interest during the month of March. As of March 15th, there was short interest totalling 6,270,000 shares, a growth of 5.7% from the February 29th total of 5,930,000 shares. Based on an average daily trading volume, of 1,970,000 shares, the days-to-cover ratio is currently 3.2 days.

AlloVir Stock Down 4.6 %

Shares of ALVR opened at $0.77 on Wednesday. The business’s 50-day moving average price is $0.72 and its 200-day moving average price is $1.27. AlloVir has a twelve month low of $0.62 and a twelve month high of $6.12. The stock has a market cap of $88.16 million, a PE ratio of -0.42 and a beta of 0.86.

Insider Buying and Selling

In related news, CEO Diana Brainard sold 41,421 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $0.67, for a total value of $27,752.07. Following the transaction, the chief executive officer now directly owns 822,321 shares of the company’s stock, valued at approximately $550,955.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have sold 103,830 shares of company stock valued at $69,465. 39.97% of the stock is owned by insiders.

Institutional Investors Weigh In On AlloVir

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Middle East FZE bought a new stake in shares of AlloVir during the fourth quarter valued at about $26,000. Ensign Peak Advisors Inc increased its position in shares of AlloVir by 27.0% during the third quarter. Ensign Peak Advisors Inc now owns 7,300 shares of the company’s stock valued at $58,000 after buying an additional 1,550 shares during the period. Tower Research Capital LLC TRC increased its position in shares of AlloVir by 315.9% during the second quarter. Tower Research Capital LLC TRC now owns 8,722 shares of the company’s stock valued at $30,000 after buying an additional 6,625 shares during the period. Jane Street Group LLC bought a new stake in shares of AlloVir during the first quarter valued at about $69,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of AlloVir during the second quarter valued at about $40,000. 66.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on ALVR shares. JPMorgan Chase & Co. downgraded shares of AlloVir from an “overweight” rating to an “underweight” rating in a report on Friday, December 22nd. Bank of America downgraded shares of AlloVir from a “buy” rating to an “underperform” rating in a report on Tuesday, December 26th. SVB Leerink downgraded shares of AlloVir from an “outperform” rating to a “market perform” rating in a report on Friday, December 22nd. Leerink Partnrs downgraded shares of AlloVir from an “outperform” rating to a “market perform” rating in a report on Friday, December 22nd. Finally, Piper Sandler downgraded shares of AlloVir from an “overweight” rating to a “neutral” rating in a report on Friday, December 22nd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $18.67.

View Our Latest Research Report on ALVR

AlloVir Company Profile

(Get Free Report)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Read More

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.